Psoriatic Arthritis (PsA) Treatment Market Report, By Treatment Type (Medications, NSAIDs (Nonsteroidal Anti-Inflammatory Drugs), Mode of Administration (Oral, Injectable, Topical); Patient Type (Newly Diagnosed, Moderate to Severe, Psoriatic Arthritis, Refractory or Resistant Cases); End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Homecare Settings); and Regions 2024-2032

Market Overview:

"The global Psoriatic Arthritis (PsA) treatment market size reached US$ 10.8 billion in 2023. Looking forward, Reports and Insights expects the market to reach US$ 20.5 billion in 2032, exhibiting a growth rate (CAGR) of 7.4% during 2024-2032."

Report Attributes	Details
Base Year	2023
Forecast Years	2024-2032
Historical Years	2021-2023
Market Growth Rate (2024-2032)	7.4%

Psoriatic arthritis (PsA) is a chronic autoimmune disease that affects individuals with psoriasis, causing inflammation in the joints and skin. The exact cause of PsA remains unclear, but both genetic and environmental factors are believed to contribute. While symptoms can develop at any age, individuals aged between 30 and 50 years of age are more likely to affected. Common symptoms include joint pain, swelling, and stiffness, often accompanied by psoriatic skin lesions. If left untreated, PsA can lead to irreversible joint damage and disability, highlighting the importance of early diagnosis and intervention.

Several treatment options exist for managing PsA, including medications, physical therapy, and lifestyle changes. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Antirheumatic Drugs (DMARDs), and biologics are commonly prescribed to alleviate symptoms and slow disease progression. Traditional therapies aim to reduce inflammation and manage pain, while advanced biologics target specific components of the immune system to achieve better outcomes.

Recent advancements in PsA treatment involve a growing array of targeted therapies and innovative drugs that offer improved efficacy and fewer side effects. Also, surgical interventions may be considered for severe cases, providing relief and restoring joint function. The management of PsA involves a multidisciplinary approach, incorporating rheumatologists, dermatologists, and physical therapists.

Some key trends in the field include a shift towards personalized medicine, increased adoption of biologics, and rising focus on developing novel therapies. The market is witnessing significant investments in Research and Development (R&D), leading to groundbreaking discoveries and the introduction of more effective treatment options. Overall, advancements in PsA treatment contribute to enhanced patient outcomes and an improved quality of life for those affected by this chronic condition.

Psoriatic Arthritis (PsA) Treatment Market Trends and Drivers:

Factors such as rising demand for effective treatments driven by the increasing prevalence of PsA worldwide, often coexisting with psoriasis, are supporting market growth. Rising awareness among patients and healthcare professionals about the importance of early diagnosis and intervention is also leading to inclining demand for PsA medications. Also, advancements in medical research and technology have resulted in the development of innovative drugs and therapies, thereby having a positive impact on the adoption of PsA treatments.

In addition, the trend toward personalized medicine has gained significant momentum, with a focus on tailoring treatments to individual patient needs, further driving the demand for specialized PsA medications. Moreover, the integration of biologics into treatment regimens has shown significant success, and this coupled with the rapid expansion of healthcare services, including patient education and support programs, is enhancing accessibility to PsA treatment.

Countries with higher PsA treatment rates often have a combination of factors, including a larger population base, a higher prevalence of PsA, and increased healthcare infrastructure. Developed countries such as the United States, Germany, and the United Kingdom account for significant PsA treatment rates due to well-established healthcare systems and a higher awareness of autoimmune conditions.

In terms of trends, ongoing R&D, coupled with collaborations between pharmaceutical companies and research institutions, continues to drive the introduction of new medications and drugs. The global PsA treatment market is characterized by a dynamic landscape, with emerging economies contributing to steady market growth.

Psoriatic Arthritis (PsA) Treatment Market Restraining Factors:

Among the major factors restraining market growth include high cost associated with many PsA medications and therapies, which limits accessibility for a substantial portion of the population. Another major factor is the potential for adverse effects and complications with PsA medications leading to patient concerns and reluctance to pursue treatment. Side effects such as immunosuppression and increased susceptibility to infections may outweigh the perceived benefits for some individuals, impacting treatment adherence. Also, the limited efficacy of existing treatments for certain patients poses a significant challenge, and not all individuals respond positively to available medications, necessitating alternative or combination therapies. This variability in treatment outcomes complicates the management of PsA and contributes to a restrained preference for existing treatments.

In addition, regulatory hurdles and delays in the approval process for new PsA medications can slow down potential market growth. Stringent regulatory requirements and extensive clinical trials can extend the time it takes for innovative treatments to reach the market, limiting the introduction of new therapeutic options. Furthermore, insufficient awareness and understanding of PsA among healthcare professionals and the general public can result in delayed diagnosis and treatment initiation.

Psoriatic Arthritis (PsA) Treatment Market Player Opportunities:

Leading players in the global Psoriatic Arthritis (PsA) treatment market can focus on the development of novel biologics and targeted therapies tailored to specific patient profiles and open up new avenues for growth. Investing in research and development to identify and address unmet medical needs can also enhance competitive edge. Strategic collaborations and partnerships between pharmaceutical companies and healthcare providers are also essential for the integration of comprehensive PsA care. Establishing networks for patient education, support services, and improved diagnostics can enhance the overall treatment experience, promoting higher adoption rates.

Also, advancements in digital health technologies offer opportunities for companies to leverage telemedicine and remote monitoring solutions. Providing virtual consultations and monitoring tools can enhance patient engagement and convenience, potentially increasing treatment adherence and overall market growth. In addition, expansion into emerging markets with a focus on affordability and accessibility can enable reaching into previously untapped patient pools. Tailoring pricing models and treatment approaches to suit the diverse healthcare landscapes of different regions can stimulate demand and revenue growth.

Investing in patient-centric initiatives, including adherence programs, support groups, and educational campaigns, can also enhance the overall patient experience and satisfaction. Improved patient outcomes and positive experiences contribute to brand loyalty and market dominance. By focusing on innovation, strategic collaborations, digital health integration, global expansion, and patient-centric initiatives, companies can position themselves for sustained growth and success in this dynamic healthcare landscape.

Psoriatic Arthritis (PsA) Treatment Market Segmentation:

By Treatment Type

• Medications
• NSAIDs (Nonsteroidal Anti-Inflammatory Drugs)
• DMARDs (Disease-Modifying Antirheumatic Drugs)
• Biologics
• Physical Therapy
• Lifestyle Modifications

The biologics segment is expected to account for largest revenue share over the forecast period, primarily due to increasing adoption of biologics for their targeted approach in modulating the immune system, offering higher efficacy in managing psoriatic arthritis symptoms. Biologics have shown promising results in clinical trials, gaining preference among healthcare professionals and patients alike in recent times.

By Mode of Administration

• Oral
• Injectable
• Topical

Among the mode of administration segments, the injectable segment is expected to account for largest revenue share. This is attributed to the efficiency and quick onset of action offered by injectable formulations, providing patients with a more direct and potent delivery of medications. The preference for injectables is further justified by the increasing availability of user-friendly injection devices and the convenience this more of administration offers.

By Patient Type

• Newly Diagnosed
• Moderate to Severe Psoriatic Arthritis
• Refractory or Resistant Cases

Among the patient type segments, the moderate to severe psoriatic arthritis segment is expected to account for largest revenue share over the forecast period. This projection is supported by the fact that moderate to severe cases often require more aggressive and specialized treatment approaches, including the use of biologics and Disease-Modifying Antirheumatic Drugs (DMARDs). The complexity of these cases is driving incline in demand for advanced treatment options, and this is contributing to steady revenue growth of this patient type segment.

By End User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Homecare Settings

Among the end-user segments, the hospitals segment is expected to account for largest revenue share. Hospitals serve as a key setting for comprehensive patient care, offering a range of specialized services, including diagnostics, medication administration, and surgical interventions when required. The centralized nature of hospital settings facilitates efficient management of patients with psoriatic arthritis, lends a level of security and safety among individuals, and accounts for higher adoption of various treatment options.

By Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Italy
• Spain
• Russia
• Poland
• Benelux
• Nordic
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• South Korea
• ASEAN
• Australia & New Zealand
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• Saudi Arabia
• South Africa
• United Arab Emirates
• Israel
• Rest of MEA

The global Psoriatic Arthritis (PsA) treatment market is divided into five key regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is a leading market, with the United States being a significant contributor due to a high prevalence of PsA and robust healthcare infrastructure in the country. In Europe, countries such as Germany, the United Kingdom, and France play key roles in the PsA treatment market, driven by a collectively large patient population and advanced healthcare systems. Asia Pacific market share growth rate is rapid, driven by major revenue contribution from countries such as China and Japan, owing to increasing awareness, rising healthcare expenditures, and growing PsA patient pool.

Rising prevalence of PsA, greater awareness leading to early diagnosis, and continuous advancements in treatment options are among the key factors driving revenue growth of these major regional markets. Increasing recognition of PsA as a distinct and prevalent condition is also supporting increasing demand for effective treatments, and this trend is expected to continue to gain traction.

Leading Companies in Psoriatic Arthritis (PsA) Treatment Market & Competitive Landscape:

The competitive landscape in the global Psoriatic Arthritis (PsA) treatment market is characterized by the presence of established pharmaceutical companies, biotech firms, and healthcare providers. Leading companies are adopting strategic approaches to maintain their positions and expand their consumer base. A key strategy is investing in research and development to introduce innovative therapies and medications, providing a competitive edge in terms of efficacy and safety. Collaborations and partnerships with healthcare providers and patient advocacy groups are becoming increasingly common, facilitating comprehensive patient care and ensuring a broader reach. In addition, market leaders are focusing on global expansion, tailoring their products to regional needs and regulatory requirements. Digital health integration, including telemedicine services and remote monitoring solutions, is another strategic move to enhance patient engagement and accessibility. Overall, a combination of research-driven innovation, strategic collaborations, and a global perspective are key elements shaping the competitive landscape in the PsA treatment market.

These companies include:

• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson
• Pfizer Inc.
• Eli Lilly and Company
• Novartis International AG
• Bristol Myers Squibb Company
• UCB S.A.
• Celgene Corporation (acquired by Bristol Myers Squibb)
• AstraZeneca PLC
• Boehringer Ingelheim International GmbH
• Merck & Co., Inc.
• Gilead Sciences, Inc.
• Roche Holding AG
• Sanofi S.A.

Recent Development:

• January 2024: UCB, which is a pharmaceutical company, had recently introduced Bimzelx as a new treatment for Psoriatic Arthritis (PsA). Notably, Bimzelx has demonstrated efficacy even in individuals with a history of unresponsiveness to previous treatments. The drug has received approval in various countries, including Japan, and has been sanctioned for PsA treatment in the European Union and the United Kingdom, while other countries, including Australia, Canada, Switzerland, and China, are considering approving the drug. A review, published in January 2024, evaluated Bimzelx's performance in comparison to other available treatments for psoriasis and PsA. The significance of this review lies in addressing the limited direct comparative data, providing valuable insights for healthcare professionals in determining the appropriate treatment. The findings of the review highlighted Bimzelx's superior efficacy in both PsA and psoriasis, with a safety profile comparable to existing treatments. This development marks a significant advancement in PsA therapeutics, offering a promising option for individuals with limited treatment responsiveness.

• October 2023: Novartis, a global leader in immuno-dermatology and rheumatology, announced the approval by the US Food and Drug Administration (FDA) of an intravenous (IV) formulation of Cosentyx (secukinumab) for treating adults with Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). Notably, Cosentyx is the sole FDA-approved IV treatment specifically targeting and inhibiting interleukin-17A (IL-17A) and stands as the exclusive non-tumor necrosis factor alpha (TNF-α) IV option across these indications. The new IV formulation offers patients a monthly 30-minute, weight-based dosing option without the need for pre-medication and lab monitoring. Cosentyx, a fully human biologic, addresses IL-17A, which is a key cytokine involved in the inflammation associated with PsA, moderate to severe plaque psoriasis, ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA).

• August 2022: The Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of STELARA (ustekinumab) by the U.S. Food and Drug Administration (FDA) for treating pediatric patients aged six years old and above with active psoriatic arthritis. This approval addresses a rare condition resembling adult PsA, impacting five to eight percent of children and adolescents with chronic inflammatory arthritis. Notably, STELARA, a fully human monoclonal antibody, selectively inhibits both interleukin (IL)-12 and IL-23, which are cytokines believed to play a crucial role in regulating the hyperactive inflammatory response seen in various autoimmune diseases. With this approval, two out of four indications for STELARA now encompass pediatric patients, marking an expansion of its treatment profile since its initial approval in 2009 for adults dealing with moderate to severe plaque psoriasis (PsO).

Psoriatic Arthritis (PsA) Treatment Market Research Scope

Report Metric	Report Details
Market size available for the years	2021-2023
Base Year	2023
Forecast Period	2024-2032
Compound Annual Growth Rate (CAGR)	7.4%
Segment covered	Treatment Type, Mode of Administration, Patient Type, End User
Regions Covered	North America: The U.S. Canada Latin America: Brazil, Mexico, Argentina, & Rest of Latin America Asia Pacific: China, India, Japan, Australia & New Zealand, ASEAN, & Rest of Asia Pacific Europe: Germany, The U.K., France, Spain, Italy, Russia, Poland, BENELUX, NORDIC, & Rest of Europe The Middle East & Africa: Saudi Arabia, United Arab Emirates, South Africa, Egypt, Israel, and Rest of MEA
Fastest Growing Country in Europe	Germany
Largest Market	North America
Key Players	AbbVie Inc., Amgen Inc., Johnson & Johnson, Pfizer Inc., Eli Lilly and Company, Novartis International AG, Bristol Myers Squibb Company, UCB S.A., Celgene Corporation (acquired by Bristol Myers Squibb), AstraZeneca PLC, Boehringer Ingelheim International GmbH, Merck & Co., Inc., Gilead Sciences, Inc., Roche Holding AG, Sanofi S.A.